semaglutide nejm weight loss New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) https://nej.md/444aW7f Cagrilintide–Semaglutide for Overweight and Diabetes (REDEFINE 2 phase 3a trial) https://nej.md/4ehQwLk Once-Weekly Semaglutide in Persons with

95% CI, -1.19 to 0.02), with high heterogeneity (I = 83.3%)

It also means the dosing window is more flexible than peptides that require precise timing around growth hormone release patterns

Severe abdominal pain, inability to pass gas, persistent vomiting, dizziness, fainting, or black/tarry stools require immediate medical attention

Differential impact of SARS-coV-2 isolates, namely, the wuhan strain, delta, and omicron variants on erythropoiesis

Conflict of interest: JAR, AFB, STB, KSF, JFJ, LMJ, CP, LS, AS, LBK, TTL, JP-W, HW, SG, CGS, GS, TA, HCCH, JN, and SJP are current or former Novo Nordisk employees and/or shareholders

From a weight-inclusive perspective, the goal is not to shame or glorify these drugs, but to center informed consent, body autonomy, and holistic well-being